Anna Tasegian

This study identifies and optimizes TEAD-targeted glue degraders using an aldehyde-mediated degron mechanism, achieving improved degradation potency and kinetics.

The paper identifies a potent BRD9 degrader, AMPTX-1, which selectively recruits BRD9 to DCAF16, leading to its degradation in vivo.

This study investigates how inflammation and IL-4 regulate LRRK2 expression and activity in immune cells, revealing cell-specific effects and the role of the LRRK2-R1441C mutation.

The paper investigates the role of LRRK2 in lysozyme expression in Paneth cells and finds that LRRK2 is not required for lysozyme expression in the murine gut and is not expressed in Paneth cells.

This study compares Type I and Type II LRRK2 inhibitors, showing Type II compounds are more potent against wild-type LRRK2 and fail to dephosphorylate specific biomarker sites, suggesting conformational selectivity.